Please use this identifier to cite or link to this item:
|Title:||Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine|
George K.K. Lau
Mohd Ismail bin Merican
Khin Maung Win
Queen Mary Hospital Hong Kong
Cliniques Universitaires Saint-Luc, Brussels
Middlemore Hospital, Auckland
Kuala Lumpur Hospital
Yangon General Hospital
Hopital de l'Hotel-Dieu CHU Lyon
University of Queensland
Glaxosmithkline Biologicals S.A.
Universita degli Studi di Parma
|Keywords:||Biochemistry, Genetics and Molecular Biology;Immunology and Microbiology;Medicine;Veterinary|
|Citation:||Vaccine. Vol.25, No.51 (2007), 8585-8597|
|Abstract:||Induction of curative immune responses by therapeutic vaccination in chronic viral infections such as chronic hepatitis B (CHB) is expected to be facilitated by reduction of viral load by antiviral treatment. In this open label, controlled, randomized study, 195 patients with HBeAg positive CHB were randomized to receive 12 doses of HBsAg with AS02B adjuvant candidate vaccine plus lamivudine daily for 52 weeks or lamivudine daily alone. The combined administration of vaccine and lamivudine was safe and well tolerated, but did not improve the HBe seroconversion rate (18.8%) when compared to treatment with lamivudine alone (16.1%) (p = 0.6824). Despite induction of a vigorous HBsAg-specific lymphoproliferative response, cytokine production and anti-HBs antibodies, therapeutic vaccination with an adjuvanted HBsAg vaccine administered concomitantly with lamivudine did not demonstrate superior clinical efficacy in HBeAg positive CHB patients as compared to lamivudine therapy alone. © 2007 Elsevier Ltd. All rights reserved.|
|Appears in Collections:||Scopus 2006-2010|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.